ARTICLE | Clinical News
Qinprezo vosaroxin regulatory update
December 14, 2015 8:00 AM UTC
Sunesis submitted an MAA to EMA for Qinprezo vosaroxin to treat relapsed/refractory acute myelogenous leukemia (AML) in patients ages >=60. The quinolone derivative intercalates DNA and inhibits topoisomerase II (TOP2). ...